Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Counting Market

Cell Counting Market Trends

Report ID: GMI8496
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Cell Counting Market Trends

Technological advancements in techniques, such as flow cytometry and automated hematology analyzers for improving accuracy and efficiency will play a key role in the market growth. These innovations are enabling researchers to obtain more precise and reliable cell counts for enhancing their ability to analyze samples and conduct experiments effectively. As technology continues to evolve, these techniques will further enhance to offer even greater accuracy and efficiency in cell counting processes. This ongoing refinement ensures that researchers can rely on cutting-edge tools to meet the demands of increasingly complex scientific inquiries in the future. For instance, in August 2022, DeNovix Inc announced the development of two dedicated nuclei counting apps that distinguish isolated nuclei and intact cells from debris.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cell counting market size was valued at over USD 11.6 billion in 2023 and is expected to exceed USD 20.6 by 2032 driven by the rising incidence of chronic diseases such as HIV, measles, diphtheria, cancer, and blood disorders.

The consumables and reagents segment is slated to depict 6.7% CAGR from 2024-2032 as they are essential in facilitating accurate and efficient cell counting processes.

North America cell counting industry size is expected to surpass USD 7.7 billion by 2032 due to the rising investments in healthcare infrastructure and escalating R&D activities.

Prominent cell counting companies include Abbott Laboratories, Agilent Technologies, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Biote, Instruments, Inc., ChemoMetec A/S, DeNovix, Merck KGaA, NanoEnTek Inc, Olympus Corporation, Sysmex Corporation, and Thermo Fisher Scientific Inc.